Aclipse Therapeutics announced on September 22, 2026, an agreement that provides it with the option to acquire Cypress BioPharma. The financial terms of the agreement were not disclosed.
King of Prussia, Pennsylvania-based Aclipse Therapeutics, a clinical-stage biopharmaceutical company focused on developing therapies for chronic, rare, and severe diseases, stated the agreement is intended to launch a Phase 2 study in childhood nephrotic syndrome and expand its renal development capabilities.